Regeneron Pharmaceuticals, Inc.
—- Market cap
- —
- Debt
- —
- Cash
- −$3.12B
Complete market value, debt and cash evidence is required for enterprise value.
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: REGN stock price vs PG: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at PG's multiple
Needs PG P/E.
Implied fair value · at REGN's multiple
Needs Annual EPS, REGN P/E.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Higher is better
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Eight period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
REGENERON PHARMACEUTICALS, INC. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
PROCTER & GAMBLE Co · implied price per share
Reporting currency could not be verified.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
PG · not enough data.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
AMGEN INC
REGN vs AMGN
PFIZER INC
REGN vs PFE
BRISTOL MYERS SQUIBB CO
REGN vs BMY
BIOGEN INC.
REGN vs BIIB
GILEAD SCIENCES, INC.
REGN vs GILD
Seagate Technology Holdings plc
REGN vs STX
COLGATE PALMOLIVE CO
REGN vs CL
KIMBERLY CLARK CORP
REGN vs KMB
CHURCH & DWIGHT CO INC /DE/
REGN vs CHD
CLOROX CO /DE/
REGN vs CLX
Johnson & Johnson
REGN vs JNJ
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe REGN can sustain its superior margin profile while stabilizing growth and maintaining its conservative balance sheet, then the current valuation discount versus PG looks attractive enough to consider adding REGN because it trades at materially lower earnings and EBITDA multiples despite stronger net and EBITDA margins.
REGN trades at 15.8x P/E versus PG at 23.3x, indicating a clear earnings multiple discount. On enterprise-value measures, REGN is also cheaper at 9.7x EV/EBITDA versus PG’s 17.1x and 3.8x EV/Revenue versus 4.5x, which supports a valuation gap in REGN’s favor.
Supporting Metrics